← Browse by Condition
Medical Condition

adenocarcinoma

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — adenocarcinoma Clinical Trials

How many clinical trials are currently recruiting for adenocarcinoma?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for adenocarcinoma?
adenocarcinoma research spans Phase 1 (2 trials), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a adenocarcinoma clinical trial?
Eligibility criteria for adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
1
Phase 3
1
Top Sponsors
University Hospital, Clermont-Ferrand 1 trial
QuantumLeap Healthcare Collaborative 1 trial
Institute of Cancer Research, United Kingdom 1 trial
University of Chicago 1 trial
Institut Claudius Regaud 1 trial

Recruiting Clinical Trials

NCT06649474
Recruiting
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
Enrollment
100 pts
Location
France
Sponsor
University Hospital, Clermont-...
View Trial →
NCT05868226 Phase 1, Phase 2
Recruiting
PRE-ISPY Phase I/II Oncology Platform Program
Enrollment
280 pts
Location
United States
Sponsor
QuantumLeap Healthcare Collabo...
View Trial →
NCT02973828
Recruiting
PRIMER: Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided Radiotherapy
Enrollment
173 pts
Location
United Kingdom
Sponsor
Institute of Cancer Research, ...
View Trial →
NCT04361708 Phase 1
Recruiting
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
Enrollment
54 pts
Location
United States
Sponsor
University of Chicago
View Trial →
NCT05581121 Phase 3
Recruiting
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Enrollment
510 pts
Location
Czechia, France, Ita...
Sponsor
Institut Claudius Regaud
View Trial →

Related Conditions

pancreatic cancer (1) resectable pancreatic adenocarcinoma (1) resectable esophageal cancer (1) resectable gastric or gastroesophageal junction adenocarcinoma (1) oesophagogastric cancer (1) her2 positive breast cancer (1) metastatic cancer (1) metastatic breast cancer (1) metastatic (1) her2 positive metastatic breast cancer (1) her2 mutation related tumors (1) her 2 protein overexpression (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology